The Carlyle Group Inc. (CG)
Automate Your Wheel Strategy on CG
With Tiblio's Option Bot, you can configure your own wheel strategy including CG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CG
- Rev/Share 12.4338
- Book/Share 17.7631
- PB 2.5829
- Debt/Equity 0.0
- CurrentRatio 4.6987
- ROIC 0.1887
- MktCap 16568919680.0
- FreeCF/Share -2.077
- PFCF -22.1925
- PE 15.203
- Debt/Assets 0.0
- DivYield 0.0305
- ROE 0.1858
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Upgrade | CG | TD Cowen | Hold | Buy | -- | $56 | May 14, 2025 |
Downgrade | CG | Oppenheimer | Outperform | Perform | -- | -- | March 19, 2025 |
Upgrade | CG | Wolfe Research | Peer Perform | Outperform | -- | $60 | Jan. 3, 2025 |
Initiation | CG | Wells Fargo | -- | Equal Weight | -- | $42 | Sept. 12, 2024 |
Initiation | CG | Redburn Atlantic | -- | Buy | -- | $55 | Aug. 27, 2024 |
News
Carlyle's Jeff Currie: OPEC supply increases have been bearish surprise for the market
Published: May 22, 2025 by: CNBC Television
Sentiment: Negative
Jeff Currie, Carlyle chief strategy officer of energy pathways, joins CNBC's 'Squawk on the Street' to discuss outlooks on energy.
Read More
bluebird bio shares soar after amended buyout offer from Carlyle, SK Capital
Published: May 14, 2025 by: Proactive Investors
Sentiment: Positive
Shares of bluebird bio Inc (NASDAQ:BLUE) surged 50% on Wednesday after the gene therapy developer announced an amended acquisition agreement with private equity firms Carlyle and SK Capital, offering shareholders a higher upfront cash payout. The revised deal includes a $5 per share cash offer, replacing a previous bid that had offered $3 per share upfront and a contingent value right (CVR) of $6.84 per share, payable if certain sales milestones were met.
Read More
Carlyle Q1 Earnings Top Estimates, Revenues & AUM Increase Y/Y
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
CG's first-quarter results reflect increases in revenues and the AUM balance. Expenses also decline year over year.
Read More
The Carlyle Group, Inc. (CG) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
The Carlyle Group, Inc. (NASDAQ:CG ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Daniel Harris - Partner & Head, Public Investor Relations Harvey Schwartz - CEO & Director John Redett - CFO & Head, Corporate Strategy Conference Call Participants Ben Budish - Barclays Alex Blostein - Goldman Sachs Patrick Davitt - Autonomous Research Brian Bedell - Deutsche Bank Brian McKenna - Citizens Ken Worthington - JPMorgan Mike Brown - Wells Fargo Michael Cyprys - Morgan Stanley Bill Katz - TD Cowen Kyle Voigt - KBW Operator Good day, and thank you for standing by. …
Read More
Acentra Health Awarded $27.5 Million Contract from California Medicaid to Continue Providing Preadmission Screening and Resident Review (PASRR) Services
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Acentra Health awarded $27.5 million contract from California Medicaid to continue providing mental health preadmission screenings for long-term care.
Read More
The More It Underperforms, The More I Buy
Published: April 27, 2025 by: Seeking Alpha
Sentiment: Positive
Three sectors of the market have soared in recent years. However, there are laggards in each of them. I discuss why these underperformers are a golden buying opportunity for investors today.
Read More
Socially Determined and Acentra Health Partner to Advance Whole Person, Whole Population Healthcare through Enhanced Analytics
Published: April 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
WASHINGTON, April 24, 2025 (GLOBE NEWSWIRE) -- Socially Determined, a social risk analytics and solutions company leading the integration of health and social care, and Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, have partnered to deliver the power of data, raw computing, and AI analytics to help state healthcare agencies more accurately predict and target interventions that improve health outcomes for individuals and communities, and reduce program costs. The partnership allows Acentra Health to leverage Socially Determined's nationwide access to …
Read More
Carlyle (CG) Surges 11.7%: Is This an Indication of Further Gains?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Carlyle (CG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Carlyle seeks buyers for Colombian oil producer
Published: March 20, 2025 by: Reuters
Sentiment: Neutral
Private equity group Carlyle is seeking a buyer for its Colombian oil producer SierraCol for around $1.5 billion, according to people with knowledge of the matter.
Read More
SoftBank Group to Acquire Ampere Computing
Published: March 19, 2025 by: Business Wire
Sentiment: Neutral
TOKYO & SANTA CLARA, Calif.--(BUSINESS WIRE)--SoftBank Group Corp. (TSE: 9984, “SoftBank Group”) today announced that it will acquire Ampere® Computing, a leading independent silicon design company, in an all-cash transaction valued at $6.5 billion. Under the terms of the agreement, Ampere will operate as a wholly owned subsidiary of SoftBank Group and retain its name. As part of the transaction, Ampere's lead investors – Carlyle (NASDAQ: CG) and Oracle Corp. (NYSE: ORCL) – are selling their re.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bluebird Bio, Inc. - BLUE
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Published: March 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Read More
bluebird bio Investor Alert: Is the Proposed Acquisition of bluebird bio Fair to bluebird bio Investors - Kehoe Law Firm, P.C. Investigating - BLUE
Published: March 12, 2025 by: Accesswire
Sentiment: Neutral
PHILADELPHIA, PA / ACCESS Newswire / March 12, 2025 / Kehoe Law Firm, P.C. continues its investigation on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness of the proposed acquisition of bluebird bio by "funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP ("SK Capital") in collaboration with a team of highly experienced biotech executives.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Published: March 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Read More
PAX vs. CG: Which Stock Is the Better Value Option?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Financial - Investment Management stocks have likely encountered both Patria Investments (PAX) and Carlyle Group (CG). But which of these two stocks is more attractive to value investors?
Read More
NSM Insurance Group Announces Definitive Agreement for New Mountain Capital to Acquire Its U.S. Commercial Insurance Division
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
CONSHOHOCKEN, Pa. , Feb. 24, 2025 /PRNewswire/ -- NSM Insurance Group ("NSM"), a global specialty insurance provider, announced today it has signed a definitive agreement to sell its U.S. commercial insurance division to New Mountain Capital ("New Mountain"), a leading growth-oriented investment firm with over $55 billion in assets under management.
Read More
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by bluebird bio, Inc. (NASDAQ: BLUE) and its board of directors concerning the proposed acquisition of the company by Carlyle (NASDAQ: CG) and SK Capital Partners, LP. Stockholders will receive $3.00 and a contingent value right of $6.84 for each share of bluebird bio stock that they hold.
Read More
bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
PHILADELPHIA, PA / ACCESS Newswire / February 21, 2025 / Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness of the proposed acquisition of bluebird bio by "funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital") in collaboration with a team of highly experienced biotech executives.
Read More
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
Published: February 21, 2025 by: Business Wire
Sentiment: Neutral
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”) in collaboration with a team of highly experienced biotech executives. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. Carlyle and SK Capital will provide bluebird prim.
Read More
Higher Fee Revenues, Brighter Outlook Boost Mood Of Private Equity's Big 4
Published: February 21, 2025 by: Seeking Alpha
Sentiment: Positive
Record revenues from management fees and a brighter outlook for M&A in the year ahead helped private equity's Big Four close 2024 on a high note. The average net positivity score for the four largest listed alternative asset managers - Apollo Global Management, Blackstone, The Carlyle, and KKR - rose to its highest level in several years, according to an S&P Global Market Intelligence analysis.
Read More
Farmfront Announces Commercial Partnership with BF Group to Supply Irrigation Solutions
Published: February 18, 2025 by: Business Wire
Sentiment: Neutral
MILAN--(BUSINESS WIRE)--Farmfront Group (“Farmfront”), a leading global platform of irrigation providers backed by global investment firm Carlyle (NASDAQ: CG), announces that it has signed a strategic commercial partnership and supply agreement with BF International Best Fields Best Foods Limited (“BFI”), a company of BF S.p.A. group (“BF Group”) to provide irrigation solutions to its subsidiary, BFI. The agreement is intended to support BF Group's international expansion plans and support agro.
Read More
The old economy is still very much out of favor right now, says Carlyle's Jeff Currie
Published: February 13, 2025 by: CNBC Television
Sentiment: Negative
Jeff Currie, Carlyle chief strategy officer of energy pathways, joins 'Squawk Box' to discuss impact of President Trump's tariffs on commodities, impact of steel and aluminum tariffs on producer inflation, state of U.S. oil production, and more.
Read More
Carlyle Group enters Indian auto parts industry with Highway-Roop platform buy
Published: February 13, 2025 by: Reuters
Sentiment: Positive
U.S.-based investment firm Carlyle Group has entered India's auto components market by buying a controlling stake in an entity formed by the combination of Indian auto parts companies Highway Industries and Roop Automotives.
Read More
Carlyle Q4 Earnings Miss Estimates, Revenues & AUM Increase Y/Y
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Negative
CG's fourth-quarter 2024 results benefit from growth in segment fee revenues. Yet, an increase in expenses acts as a headwind.
Read More
The Carlyle Group Inc. (CG) Q4 2024 Earnings Call Transcript
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
The Carlyle Group Inc. (NASDAQ:CG ) Q4 2024 Earnings Conference Call February 11, 2025 8:30 AM ET Company Participants Daniel Harris - Head of Investor Relations Harvey Schwartz - Chief Executive Officer John Redett - Chief Financial Officer and Head of Corporate Strategy Conference Call Participants Alexander Blostein - Goldman Sachs Brendan O'Brien - Wolfe Research Patrick Davitt - Autonomous Research Brian Bedell - Deutsche Bank Brian McKenna - Citizens JMP Glenn Schorr - Evercore ISI Benjamin Budish - Barclays Daniel Fannon - Jefferies William Katz - TD Cowen Kenneth Worthington - JPMorgan Michael Cyprus - Morgan Stanley Kyle Voigt …
Read More
Carlyle's slower fee growth draws questions as private-equity firm's stock falls
Published: February 11, 2025 by: Market Watch
Sentiment: Negative
Carlyle Group Inc.'s stock fell 5% on Tuesday after the private-equity firm signaled a slowdown in its fee-related earnings growth in 2025, as it leans on its private-credit arm to increase its profit.
Read More
About The Carlyle Group Inc. (CG)
- IPO Date 2012-05-03
- Website https://www.carlyle.com
- Industry Asset Management
- CEO Mr. Harvey Mitchell Schwartz
- Employees 2300